Laigo Bio
Last verified 2026-05-23. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $18.4Mattributed |
|---|---|
| Latest round | seed, $18.4M, 2026-03-23attributed |
| Founded | 2023 |
| Headquarters | Utrecht, Netherlands |
| Industry | bio |
| Stage | seed |
| Website | laigobio.com |
Biotech advancing SureTAC targeted protein degradation candidates for oncology and autoimmunity.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2026-03-23 | seed | $18.4M | undisclosed |
Detected tech stack
Nginx, PHP 7.4.33, reCAPTCHA, Slick 1.8.1, jsDelivr, cdnjs, CookieBAR, Cloudflare, jquery 3.2.1
Provenance
| Fact | Status | Basis |
|---|---|---|
| Seed, $18.4M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $18.4M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | laigobio.com, read 2026-05-23 |
| Description | self-reported | laigobio.com, read 2026-05-23 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.